Breast Cancer Research and Treatment **60:** 285–286, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Authors Index, Volume 60

Agugiaro S 267
Alhadeff JA 173
Amano G 43
Amari M 43
Ambrosini G 267
Amichetti M 267
Andersen J 219
Arcona S 173
Armatis P 71

Baldetorp B 219
Baldo C 9
Bansard J-Y 99
Bear HD 277
Becker M 81
Beex L 181
Bennett GD 135
Bernardi D 267
Blondal J 143
Bockenheimer J 211
Boes GH 181
Boetes C 235
Boilly B 251
Bourhis XL 251
Brower ST 129
Browne RJ 173
Brugnara S 267

Caffo O 267
Calberg-Bacq C-M 15
Casey G 135
Cazzolli D 267
Chao CC-K 259
Chatzistamou I 71
Chen D 107
Chen S-H 129
Chen S-C 259
Chen T-C 259
Choi I-J 173
Christensen IJ 219
Christov K 117
Ciaghi G 267
Clark LJ 167
Cochrane PJ 173
Coleman R 181
Collette J 15
Comandini D 195
Cornell D 277
Czömpöly T 71

Dancel R 153
Davis B 173
de Swart CAM 57
DeGregorio MW 63
Deroanne C 15
Diamandis EP 1
Divino CM 129
Dudorkinová D 241

Eccher C 267
Eichler HG 211

Fichtner I 81
Flower RLP 135
Foidard J-M 15
Foucher F 99
Fujiwara Y 35
Furukawa J 35
Fusco V 195

Galligioni E 267
Garcia SJ 153
Gendler S 107
Gong J 107
Grall J-Y 99
Grass L 1
Green A 117
Groenendijk RPR 235
Grubbs C 117

Hajitou A 15
Halmos G 71
Hamilton A 181
Hanna W 143
Hansen B 219
Havouis R 99
Hellmann-Blumberg U 63
Holloway C 143
Hondermarck H 251
Huldij JC 57
Ishibashi T 43
Ishida T 43
Isotalo PA 29

Jenkins DJA 1
Johnson A 201
Jost-Reuhl B 81

Kadota M 35
Kahn HJ 143
Kahán Z 71
Karp SE 277
Keemers-Gels ME 235
Kelloff G 117
Klein N 211
Klijn J 181
Koido S 107
Krásná L 241

Lange MK 173
Larsen JK 219
Latosinsky S 277
Levêque J 99
Li Y 107
Lickley L 143
Linden T 219
Little S 277
Lo Y-F 259
Lubet R 117
Lucenti A 267

Mader RM 211
Magklara A 1
Mai KT 29
Marks A 143
Masuda N 35
Matoušková E 241
Matsuura N 35
Mauriac L 181
McCoy JL 227
McCready DR 143
Mehta RG 117
Merlini L 195
Miyazaki M 35
Müller M 211

Molino A 9
Monden M 35
Moulinoux J-P 99

Narod S 143
Naso C 195
Natale N 267
Naundorf H 81
Neumann C 81
Noël A 15
Nortier JWR 57
Nusgens B 15

Ohnishi T 35
Ohuchi N 43
Ohue M 35
Ooka M 35
Ottesen GL 219

Paganini-Hill A 167
Palmer P 181
Palumbo R 195
Paredes ED 277
Paridaens R 181
Peer PGM 235
Petros JA 227
Piccart M 181
Porcile G 195
Pronzato P 195
Quinn DM 135

Repetto L 195
Reuhl T 81
Riley LB 173
Rékási Z 71
Rosso R 195
Roy J-A 181
Rubach M 57
Rucker R 227
Rudzki Z 135

Sakita I 35
Satomi S 43
Scalet A 267
Schally AV 71
Seidler FJ 153
Sekimoto M 35
Seth A 143
Shilkaitis A 117
Siah SP 135
Simoni C 195
Slotkin TA 153
Steger GG 211
Suthers G 135

Tamaki Y 35
Taras TL 63
Thung S 129
Toillon R-A 251
Tomita N 35

van den Heuvel JHM 235
van Toorn DW 57
van Tinteren H 57
van Vreckem A 181
Varga JL 71
Venturino A 195
Vermorken JB 57
Veselý P 241

Willis C 153
Wobbes T 235
Woo SLC 129
Wurz GT 63

Yang L-Y 143
Yang W 129
Yazdi HM 29

Zand RSR 1
Zani B 267
Zellenberg U 211
Zhang J 153
Zimmermann C 9

Breast Cancer Research and Treatment **60:** 287–290, 2000.
© 2000 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 60

active processed cathepsin D
in human breast cancer: usefulness as a prognostic indicator 173-179
adenylyl cyclase
β-adrenoceptors on MDA-MB-231 human breast cancer cells 153-166
adjuvant chemotherapy
and immediate breast reconstruction 267-275
framing of outcome and probability of cancer recurrence 9-14
adrenoviral vector
anti-tumor immunity induced by Interleukin-12 gene therapy in metastatic breast cancer 129-134
advanced breast cancer
is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? 195-200
randomized phase II study of FEC day 1 + 8 and FEC day 1 57-62
Amsler grid
eye problems in breast cancer patients treated with tamoxifen 167-172
antiestrogens
is ICI 182,780 an antiprogestin in addition to being an antiestrogen? 1-8
antiprogestins
is ICI 182,780 an antiprogestin in addition to being an antiestrogen? 1-8
anti-tumor immunity
T cell suppression as a mechanism for tolerance to MUC1 antigen 107-115
apoptosis
T cell suppression as a mechanism for tolerance to MUC1 antigen 107-115
aromatase inhibitor
a phase II study of liarozole in postmenopausal patients 181-188
T cell suppression as a mechanism for tolerance to MUC1 antigen 107-115

β-adrenoceptors
β-adrenoceptors on MDA-MB-231 human breast cancer cells 153-166
breast cancer cells
MCF-7 cell transformation by FGF-3 and FGF-4 15-28
RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients 143-151
screening pain experienced by women attending breast cancer screening 235-240
breast carcinoma
tamoxifen resistance 81-92
breast epithelial cells
autocrine and paracrine growth inhibitors of breast cancer cells 251-258
breast neoplasm
evaluation of stereotactic core needle biopsy (SNCB) of the breast 277-283

carcinoma extension
3D MRI of breast cancer extension 43-55
carcinoma *in situ*
of the breast 219-226
cataract
eye problems in breast cancer patients treated with tamoxifen 167-172
cell-mediated immunity
immunity to breast cancer antigens 227-234
cell replication
β-adrenoceptors on MDA-MB-231 human breast cancer cells 153-166
circulating tumor cells
RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients 143-151
compression
pain experienced by women attending breast cancer screening 235-240
cyclic AMP
β-adrenoceptors on MDA-MB-231 human breast cancer cells 153-166
cytokeratin 19 (CK19) mRNA
RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients 143-151

3D MRI
of breast cancer extension 43-55
decision board instrument
framing of outcome and probability of cancer recurrence 9-14
decision-making

framing of outcome and probability of cancer recurrence 9-14
diagnosis
detection of LOH in nipple discharge 35-41
DNA adducts
genotoxic effects of triphenylethylenes 63-70
DNA ploidy
carcinoma *in situ* of the breast 219-226
DNA synthesis
β-adrenoceptors on MDA-MB-231 human breast cancer cells 153-166
dose-intensity
randomized phase II study of FEC day 1 + 8 and FEC day 1 57-62
drugs combination
is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? 195-200
ductal carcinoma *in situ*
3D MRI of breast cancer extension 43-55

epirubicin scheduling
randomized phase II study of FEC day 1 + 8 and FEC day 1 57-62
erythrocytes
polyamine metabolism in breast cancer adenocarcinoma 99-105
estrogen receptor
tamoxifen resistance 81-92
estrogens
is ICI 182,780 an antiprogestin in addition to being an antiestrogen? 1-8
eye problems
in breast cancer patients treated with tamoxifen 167-172

FC-1271a
genotoxic effects of triphenylethylenes 63-70
first line FEC treatment
randomized phase II study of FEC day 1 + 8 and FEC day 1 57-62
5-fluorouracil
In-vivo-PK / *in-vitro*-PD model of cytotoxic activity 211-217

gene therapy
anti-tumor immunity induced by Interleukin-12 gene therapy in metastatic breast cancer 129-134
GH-RH
GH-RH antagonists in breast cancer 71-79
glaucoma
eye problems in breast cancer patients treated with tamoxifen 167-172
glucocorticoids
β-adrenoceptors on MDA-MB-231 human breast cancer cells 153-166
growth hormone-releasing hormone (GH-RH) antagonists
H-RH antagonists in breast cancer 71-79
growth inhibitors
autocrine and paracrine growth inhibitors of breast cancer cells 251-258
growth rates
the timing of treatment in breast cancer 201-209

histological grade
the timing of treatment in breast cancer 201-209
histological mapping
D MRI of breast cancer extension 43-55
histopathology
carcinoma *in situ* of the breast 219-226

ICI 182,780
is ICI 182,780 an antiprogestin in addition to being an antiestrogen? 1-8
IGF-I
GH-RH antagonists in breast cancer 71-79
IGF-I receptor
GH-RH antagonists in breast cancer 71-79
immuno assay
tamoxifen resistance 81-92
immunohistochemistry
carcinoma *in situ* of the breast 219-226
immunotherapy
anti-tumor immunity induced by Interleukin-12 gene therapy in metastatic breast cancer 129-134
Interleukin-12
anti-tumor immunity induced by Interleukin-12 gene therapy in metastatic breast cancer 129-134
invasive carcinoma
carcinoma *in situ* of the breast 219-226

liarozole
a phase II study of liarozole in postmenopausal patients 181-188
lobular carcinoma
resection margin status in lumpectomy specimens of ILC 29-33
loss of heterozygosity
detection of LOH in nipple discharge 35-41
luminal epithelial cells

temporal *in vitro* expansion of the luminal lineage of human mammary epithelial cells 241-249
lumpectomy
resection margin status in lumpectomy specimens of ILC 29-33
lymphocyte blastogenesis assay
immunity to breast cancer antigens 227-234

macular degeneration
eye problems in breast cancer patients treated with tamoxifen 167-172
mammary tissue
temporal *in vitro* expansion of the luminal lineage of human mammary epithelial cells 241-249
mammary tumors
T cell suppression as a mechanism for tolerance to MUC1 antigen 107-115
mammography
evaluation of stereotactic core needle biopsy (SNCB) of the breast 277-283
pain experienced by women attending breast cancer screening 235-240
mastectomy
adjuvant chemotherapy and immediate breast reconstruction 267-275
MCF-7
cell transformation by FGF-3 and FGF-4 15-28
metabolites
genotoxic effects of triphenylethylenes 63-70
methotrexate
In-vivo-PK / *in-vitro*-PD model of cytotoxic activity 211-217
microsatellite instability
not detected at 'BAT 25' and 'BAT 26' microsatellite markers 135-142
microsatellite markers
microsatellite instability not detected at 'BAT 25' and 'BAT 26' microsatellite markers 135-142
MUC1 antigen
T cell suppression as a mechanism for tolerance to MUC1 antigen 107-115

nipple discharge
detection of LOH in nipple discharge 35-41
NK cells
anti-tumor immunity induced by Interleukin-12 gene therapy in metastatic breast cancer 129-134

^{32}P-postlabeling
genotoxic effects of triphenylethylenes 63-70
pain
experienced by women attending breast cancer screening 235-240
PGF-3
MCF-7 cell transformation by FGF-3 and FGF-4 15-28
PGF-4
MCF-7 cell transformation by FGF-3 and FGF-4 15-28
pharmacodynamics
In-vivo-PK / *in-vitro*-PD model of cytotoxic activity 211-217
pharmacokinetics
In-vivo-PK / *in-vitro*-PD model of cytotoxic activity 211-217
polyamines
polyamine metabolism in breast cancer adenocarcinoma 99-105
primary culture
temporal *in vitro* expansion of the luminal lineage of human mammary epithelial cells 241-249
primary medical treatment
the timing of treatment in breast cancer 201-209
progestins
is ICI 182,780 an antiprogestin in addition to being an antiestrogen? 1-8
prognosis
polyamine metabolism in breast cancer adenocarcinoma 99-105
prognostic indicator
eye problems in breast cancer patients treated with tamoxifen 167-172
immunity to breast cancer antigens 227-234

radiotherapy fractionation
the timing of treatment in breast cancer 201-209
reconstruction
adjuvant chemotherapy and immediate breast reconstruction 267-275
resection margin
status in lumpectomy specimens of ILC 29-33
retinoic acid
a phase II study of liarozole in postmenopausal patients 181-188
reverse transcriptase-polymerase chain reaction (RT-PCR)
RT-PCR amplification of CK19 mRNA in the blood of breast cancer patients 143-151
review
evaluation of stereotactic core needle biopsy (SNCB) of the breast 277-283

salvage chemotherapy

is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? 195-200
single-agent
is salvage chemotherapy for metastatic breast cancer always effective and well tolerated? 195-200
skin expander-toxicity
adjuvant chemotherapy and immediate breast reconstruction 267-275
'split course' radiotherapy
the timing of treatment in breast cancer 201-209
stereotactic core needle biopsy
evaluation of stereotactic core needle biopsy (SNCB) of the breast 277-283
subcultivation
temporal in vitro expansion of the luminal lineage of human mammary epithelial cells 241-249
survival analysis
eye problems in breast cancer patients treated with tamoxifen 167-172

T cell suppression
as a mechanism for tolerance to MUC1 antigen 107-115
tamoxifen
eye problems in breast cancer patients treated with tamoxifen 167-172
genotoxic effects of triphenylethylenes 63-70
resistance 81-92
tolerance
T cell suppression as a mechanism for tolerance to MUC1 antigen 107-115
toremifene
genotoxic effects of triphenylethylenes 63-70
toxicity
randomized phase II study of FEC day 1 + 8 and FEC day 1 57-62
transgenic mice
T cell suppression as a mechanism for tolerance to MUC1 antigen 107-115
treatment preference
framing of outcome and probability of cancer recurrence 9-14
TSG101
in Taiwan Chinese breast cancer 259-266
tumor-associated antigens
immunity to breast cancer antigens 227-234
tumor suppressor
TSG101 in Taiwan Chinese breast cancer 259-266
tumorigenicity
MCF-7 cell transformation by FGF-3 and FGF-4 15-28

urine
polyamine metabolism in breast cancer adenocarcinoma 99-105

VEGF
MCF-7 cell transformation by FGF-3 and FGF-4 15-28
vorozole
cellular responses to vorozole 117-128

xenograft
tamoxifen resistance 81-92